Non-Solicitation Policy and Notice to Agencies and Recruiters:

IDEAYA's Non-Solicitation Policy strictly prohibits agencies and recruiters from any contact and communication with IDEAYA employees, managers, and leaders to submit unsolicited candidate resumes and/or to solicit business partnerships. Submission of unsolicited candidate resumes by agencies or recruiters with or without a contract in place with IDEAYA Biosciences Inc. will not create any implied obligation. Failure to comply with this policy will result in disqualification from current and future business opportunities with IDEAYA Biosciences. All recruiting and talent agency decisions are strictly managed by the internal IDEAYA Human Resources function. All communication by external agencies and recruiters must be directed to [email protected]. We ask that you only email your interest once.

Job Summary

About IDEAYA Biosciences:
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

When you're at IDEAYA, you will be in the midst of brilliant minds working on precision medicine therapies to help cancer patients. We are passionate and committed about being on the forefront of oncology medicine, which means we all have a high internal drive that is at the very core of every person at IDEAYA. We are inquisitive, ask deep questions, and are data-driven innovators who like to collaborate and use team work to move science forward. For more information, please see www.ideayabio.com.

Location: South San Francisco

Position Summary:
We are seeking an experienced Medical Director of Patient Safety and Pharmacovigilance to join IDEAYA.

The Medical Director, Medical Safety – ICSR provides medical leadership and clinical oversight for Individual Case Safety Report (ICSR) activities across the company’s global pharmacovigilance program. This role is primarily responsible for high-quality medical review of safety cases and serves as the key medical interface with the company’s pharmacovigilance vendor for day-to-day case processing activities.

The role partners closely with Safety Operations, who shares responsibility for vendor oversight related to case processing, quality, and compliance. Together, they ensure timely, consistent, and inspection-ready safety reporting in a growing organization.

This position is based in our South San Francisco headquarter offices and required to be onsite four days per week per our company policy.

Reporting to: Senior Medical Director, Patient Safety & Pharmacovigilance

Job Description

What you’ll do:

Serve as the primary medical expert who performs and oversees medical review of ICSRs, including complex, and medically significant cases in the oncology therapeutic area
Provide clinical assessment of adverse events, including causality, seriousness, expectedness, and review narrative content for clinical accuracy and flow
Act as the primary medical point of contact for the pharmacovigilance vendor for day-to-day ICSR-related questions and escalation

Provide medical input into vendor oversight activities, including case quality review, accuracy of triage, and regulatory submission compliance
Support development of medical review guidelines, training materials, and vendor-facing instructions

Collaborate closely with the IDEAYA Safety Operations team to ensure quality across global case processing activities by monitoring quality metrics and address non-compliance events
Conduct and oversee thorough investigations of quality events, deviations and CAPAs pertaining to case processing and regulatory compliance
Support development, implementation and tracking of CAPAs

Participate in vendor governance meetings as the medical representative

Support regulatory inspections, audits, and health authority inquiries related to ICSR processing and medical review
Contribute to the development and maintenance of SOPs and work instructions related to medical case review
Serve as the medical safety point of contact for any assigned molecule(s)
Provide safety input for aggregate safety reports, protocol amendments, investigator’s brochure, informed consent and other key regulatory safety documents.
Partner with Safety Science, Regulatory Affairs, and Clinical teams as needed on safety issues requiring medical input

Requirements:

MD (or equivalent international medical degree) with 2+ years of bedside clinical experience
5–8+ years of oncology experience in drug safety/pharmacovigilance
Strong hands-on ICSR medical review experience
Demonstrated experience working with external PV vendors or CROs
Solid knowledge of global PV regulations (FDA, EMA, ICH)
Strong medical judgment, attention to detail, and ability to work effectively in a matrix environment

All employees are expected to act with integrity and in full compliance with applicable laws, regulations, and IDEAYA policies, including IDEAYA’s Code of Conduct.

Employees must demonstrate good judgement and ethical behavior in all business activities, maintain patient and product safety as a top priority, and report any suspected violations of law or Company policy through appropriate channels

Total Rewards

Along with our inspiring mission, and highly collaborative and inclusive environment, IDEAYA offers a competitive total rewards package that reflects our pay-for-performance philosophy where employees are eligible to be considered for merit-based salary increases, company discretionary short-term incentive plan participation, and company discretionary stock option awards (based on board approval). Our comprehensive benefits package includes, but is not limited to, medical/dental/vision coverage (100% company paid for employees and 90% company paid for dependents), 401k, ESPP, and wellness programs.

The expected salary range for the role of Medical Director, Drug Safety and Pharmacovigilance is $268,000 - $331,000. The final salary offered to a successful candidate will depend on several factors that may include but are not limited to the office location where this open position is located, the final candidates’ experience within their profession, experience in the disease areas we are striving to make an impact in as a company, length of time within the industry, educational background, and performance during the interview process.

The Company complies with all laws respecting equal employment opportunities and does not discriminate against applicants with regard to any protected characteristic as defined by federal, state, and local law.

IDEAYA is an equal opportunity employer. In accordance with applicable law, IDEAYA does not discriminate in hiring or otherwise in employment based on race, color, religion, sex, national origin, age, marital or veteran status, disability, sexual orientation, or any other legally protected status. EOE/AA/Vets.

We are committed to providing reasonable accommodations to qualified individuals with disabilities. If you need assistance or an accommodation due to a disability, please get in touch with us at [email protected].

About the company

IDEAYA Biosciences develops targeted cancer therapies by combining translational biomarkers with small molecule drug discovery to identify and treat specific patient populations defined by molecular diagnostics. Its product work relies on identifying biomarkers that predict which patients will respond to a given therapy and then designing and optimizing small molecules that target those biology. The company differentiates itself by grounding drug discovery in biomarker-driven precision medicine—mapping patient subgroups to therapies rather than pursuing broad oncology indications—and by pursuing partnerships and licensing to fund R&D and reach commercialization. The goal is to deliver precise, biomarker-guided cancer treatments that improve outcomes for defined patient groups and bring those therapies to market through collaborations and eventual sales of approved drugs.

Company Size

201-500

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2015

Get referred to IDEAYA Biosciences

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA accepted darovasertib NDA review under RTOR on April 30, 2026, accelerating approval.
IDEAYA raised $323.4 million in June 2026, extending funding through multiple registrational trials.
Genentech collaboration on GDC-7035 adds pancreatic cancer optionality beyond uveal melanoma commercialization.

What critics are saying

Darovasertib's revenue depends on H2 2026 FDA approval; rejection kills launch plans.
OptimUM-02 OS remains immature, leaving Servier's adjuvant OptimUM-11 and NDA exposed.
IDE892 and IDE397 face crowded MTAP-deletion competition from Tango, Erasca, and Roche-linked programs.

What makes IDEAYA Biosciences unique

Darovasertib and crizotinib posted 6.9-month PFS in OptimUM-02 on June 1, 2026.
IDE892 targets MTAP-deleted tumors with 1,400-fold MTA-PRMT5 selectivity, differentiating from broader PRMT5 programs.
Servier and Genentech partnerships validate IDEAYA's biomarker-defined combination strategy across uveal melanoma and KRAS G12D PDAC.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

Stock Options

Employee Stock Purchase Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

InsiderTrades.com

Oct 9th, 2026

Insider selling: IDEAYA Biosciences (NASDAQ:IDYA) CEO sells 26,338 shares of stock.

Insider selling: IDEAYA Biosciences (NASDAQ:IDYA) CEO sells 26,338 shares of stock. October 9, 2026 by InsiderTrades.com Key points. * CEO Yujiro Hata sold 26,338 IDEAYA Biosciences shares at an average price of $37.41, generating approximately $985,305; his remaining direct ownership fell 3.67% to 690,695 shares. * IDEAYA shares opened at $36.06, with a market capitalization of about $3.17 billion. The company's latest quarter missed EPS expectations, reporting a loss of $1.22 per share despite revenue of $8.86 million. * Analysts maintain a "Moderate Buy" consensus, with 13 Buy, one Hold and one Sell rating and an average price target of $52.69; institutional investors own 98.29% of the stock. IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) CEO Yujiro Hata sold 26,338 shares of the company's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares of the company's stock, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. IDEAYA Biosciences trading down 0.6%. NASDAQ:IDYA opened at $36.06 on Friday. IDEAYA Biosciences, Inc. has a 1 year low of $26.05 and a 1 year high of $42.68. The firm's fifty day simple moving average is $38.13 and its 200 day simple moving average is $34.29. The firm has a market capitalization of $3.17 billion, a PE ratio of -18.59 and a beta of -0.04. IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.16). The firm had revenue of $8.86 million for the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The firm's revenue was up 8800.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) EPS. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current fiscal year. Analyst Ratings changes. Discover more Explore Exchanges Most bought stocks Hire Lawyers A number of research firms have recently commented on IDYA. Guggenheim lifted their price objective on IDEAYA Biosciences from $54.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Weiss Ratings restated a "sell (d-)" rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Citizens Jmp reiterated a "market outperform" rating and set a $42.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Finally, Truist Financial reduced their price objective on IDEAYA Biosciences from $63.00 to $59.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, IDEAYA Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $52.69. Institutional inflows and outflows. A number of large investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in IDEAYA Biosciences during the second quarter worth about $43,000. Nykredit A S bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $76,000. Fifth Third Bancorp bought a new stake in shares of IDEAYA Biosciences in the 1st quarter worth approximately $84,000. GAMMA Investing LLC grew its holdings in shares of IDEAYA Biosciences by 79.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,315 shares of the company's stock worth $89,000 after purchasing an additional 1,022 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of IDEAYA Biosciences by 26.7% during the 2nd quarter. Versant Capital Management Inc now owns 2,825 shares of the company's stock worth $105,000 after purchasing an additional 596 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock. About IDEAYA Biosciences. IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors. Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma. This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected]. Insider Buying or Selling at IDEAYA Biosciences? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for IDEAYA Biosciences and related companies. From Our Partners

PR Newswire

Sep 28th, 2026

IDEAYA Biosciences announces the promotion of Dr. Michael White to President, Research and Development.

IDEAYA Biosciences announces the promotion of Dr. Michael White to President, Research and Development. Sep 28, 2026, 06:00 ET SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ - IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026. "I am excited to announce this well-deserved promotion for Mike, as President of Research and Development. During Mike's 5-year tenure as Chief Scientific Officer, he has demonstrated exceptional leadership and has been a key driver in advancing IDEAYA's mission to deliver patient impact in areas of high unmet medical need through R&D innovation. Under Mike's leadership, I am excited to see the continued advancement of our industry leading precision medicine oncology pipeline targeting multiple solid tumor indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, among others," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences, Inc. "I am honored to take on this expanded role at such a pivotal time for IDEAYA and grateful for the extraordinary commitment of our research and development teams. We have made tremendous progress in translating our precision medicine capabilities into a deep and differentiated oncology portfolio, with late-stage programs that have the potential to establish new standards of care and early-stage programs that may open entirely new therapeutic opportunities. I am particularly excited by our ability to advance innovative small molecules and antibody-drug conjugates for molecularly defined cancers where patients continue to face significant unmet need. I look forward to building on this momentum and accelerating the delivery of transformative therapies that can meaningfully improve and extend the lives of patients with cancer," said Dr. Michael White, President, Research and Development, IDEAYA Biosciences, Inc. Dr. White has served as Chief Scientific Officer at IDEAYA Biosciences since 2021. Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups in research and development to build an oncology small-molecule clinical pipeline focused on first-in-class therapies, culminating in numerous INDs and late-stage development programs. Prior to joining Pfizer, Dr. White had a prolific over twenty-year academic career at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program. In 2015, Dr. White received the inaugural Outstanding Investigator's Award from the National Cancer Institute (NCI), the U.S. Government's principal agency for cancer research, and has authored over 150 publications with over 30,000 citations. Dr. White received his Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed postdoctoral research at Cold Spring Harbor Laboratories in New York. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's research and development strategy and objectives; the expected contributions of Dr. Michael White in his expanded role as President, Research and Development; the continued advancement of IDEAYA's precision medicine oncology pipeline; the potential of IDEAYA's late-stage programs to establish new standards of care and its early-stage programs to create new therapeutic opportunities; IDEAYA's ability to develop and advance innovative small-molecule therapies and antibody-drug conjugates for molecularly defined cancers; and the potential for IDEAYA's product candidates to improve and extend the lives of patients with cancer. These forward-looking statements are based on management's current expectations and assumptions and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks related to the timing, progress, and results of clinical trials and preclinical studies; the ability of IDEAYA to obtain and maintain regulatory approvals; uncertainties regarding the regulatory review process, including participation in the RTOR program; the potential for clinical data to differ from preliminary or interim results; the ability to successfully develop, manufacture, and commercialize product candidates; competition from other biotechnology and pharmaceutical companies; the impact of global economic conditions; IDEAYA's ability to successfully establish, protect and defend its intellectual property: and other risks described in IDEAYA's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements speak only as of the date of this press release, and IDEAYA undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investor and Media Contact IDEAYA Biosciences Joshua Bleharski Chief Financial Officer [email protected] SOURCE IDEAYA Biosciences, Inc.

PR Newswire

Sep 1st, 2026

The Melanoma Research Foundation welcomes back Jacquie Palisi, Colorado native and melanoma warrior, as emcee of the 15th Annual Denver Gala.

The Melanoma Research Foundation welcomes back Jacquie Palisi, Colorado native and melanoma warrior, as emcee of the 15th Annual Denver Gala. Melanoma Research Foundation Sep 01, 2026, 15:01 ET The Melanoma Research Foundation (MRF) will celebrate two major milestones this year as it hosts the 15th Annual Denver Gala on Thursday, September 24 at Asterisk Denver, marking 15 years of bringing the Denver melanoma community together. The Foundation also embarks upon its 30th anniversary celebrating three decades of progress, innovation and hope and recognition of the treatment breakthroughs on the horizon. The gala will once again welcome Jacquie Palisi as emcee. A fourth-generation Colorado native, Emmy Award-winning television host and passionate melanoma advocate, Palisi has made melanoma awareness and prevention a central part of her life after being diagnosed with malignant melanoma in 2005 and three additional times since. Her personal experience has fueled her commitment to educating others about the importance of early detection, sun safety and regular skin checks. DENVER, Sept. 1, 2026 /PRNewswire-PRWeb/ - The Melanoma Research Foundation (MRF) will celebrate two major milestones this year as it hosts the 15th Annual Denver Gala on Thursday, September 24 at Asterisk Denver, marking 15 years of bringing the Denver melanoma community together. The Foundation also embarks upon its 30th anniversary celebrating three decades of progress, innovation and hope and recognition of the treatment breakthroughs on the horizon. The gala will once again welcome Jacquie Palisi as emcee. A fourth-generation Colorado native, Emmy Award-winning television host and passionate melanoma advocate, Palisi has made melanoma awareness and prevention a central part of her life after being diagnosed with malignant melanoma in 2005 and three additional times since. Her personal experience has fueled her commitment to educating others about the importance of early detection, sun safety and regular skin checks. "I am incredibly honored to be returning as this year's emcee for the Melanoma Research Foundation Denver Gala. When you've experienced melanoma firsthand, this isn't just another event on my calendar, it's deeply personal," said Jacquie Palisi. "And that's why I'm so passionate about the work of the MRF. They fund groundbreaking research, support patients and families, and they continue to raise awareness that's helping to save lives every single day." Gala attendees and donors are essential to advancing the fight against melanoma and creating a lasting legacy of hope for generations to come. Funds raised through the gala will help fuel groundbreaking research and accelerate the development and approval of new treatments, expand options for melanoma patients, strengthen patient and caregiver support programs, increase education and awareness, and advance advocacy efforts that drive meaningful change across the melanoma community. During the event, IDEAYA Biosciences will be recognized with the Corporate Leadership Award for its groundbreaking contributions to melanoma treatment and research. This honor highlights the company's unwavering commitment to innovation and improving patient outcomes. The MRF will also proudly present the Humanitarian Award to Sapna Patel, MD in recognition of her commitment to fighting melanoma through exemplary patient care, cutting-edge research and scientific leadership. Finally, Rossiter Marketing will celebrate the incredible strength and courage of Arielle Gold, Enzo Rebora and Lori Rosemond, RN, honoring them for the bravery they've shown in their melanoma journeys. Gala attendees will come together to honor the melanoma community with an unforgettable evening featuring a cocktail reception, elegant seated dinner, inspiring presentations and a powerful awards ceremony. The MRF extends heartfelt gratitude to its dedicated gala co-chairs - Elise A. Barish, Gerald Falchook, MD, MS and Kimberly Neyman, MD, FAAD - along with the entire host committee, generous financial sponsors, in-kind partners and all supporters whose collective efforts are instrumental in bringing the 15th Annual Denver Gala to life. About the Melanoma Research Foundation (MRF) The Melanoma Research Foundation (MRF) is the largest independent organization devoted to melanoma. Committed to the support of medical research in finding effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about prevention, diagnosis and the treatment of melanoma and the melanoma rare subtypes. The MRF is a committed advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. The MRF's website (www.melanoma.org) is the premier source for melanoma information seekers. Find the MRF on Facebook, Twitter, Instagram and TikTok. Media Contact James Merrick, Melanoma Research Foundation, 1 202-579-3450, [email protected], melanoma.org SOURCE Melanoma Research Foundation

Pharmacally

Aug 19th, 2026

IDEAYA and Genentech Partner to Evaluate IDE892 Plus GDC-7035 in PDAC.

IDEAYA and Genentech Partner to Evaluate IDE892 Plus GDC-7035 in PDAC. IDEAYA and Genentech will evaluate IDE892 with KRAS G12D inhibitor GDC-7035 in MTAP-deleted, KRAS G12D-mutant pancreatic cancer. M.Pharm (Reg. Affairs) IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate IDE892, its investigational MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) harboring both MTAP deletion and a KRAS G12D mutation. Under the collaboration, Genentech will sponsor the clinical combination study, while IDEAYA will supply IDE892. The companies will jointly oversee the collaboration through a shared governance structure. Targeting MTAP-Deleted, KRAS G12D-Mutant PDAC. The collaboration focuses on a molecularly defined subgroup of PDAC in which MTAP deletion and KRAS G12D mutations occur together. IDEAYA estimates that these alterations co-occur in up to approximately 15% of patients with PDAC. Patients with tumors carrying both alterations currently have no approved targeted treatment options. IDEAYA stated that combining a PRMT5 inhibitor with a KRAS G12D-specific inhibitor may have the potential to produce deeper and more durable responses in this genetically defined patient population. The new combination therefore brings together two targeted investigational approaches designed to address distinct molecular features of these tumors. IDE892 development program expands. IDEAYA is currently evaluating IDE892 in a Phase 1 study of monotherapy and combination therapy in patients with MTAP-deleted advanced solid tumors (NCT07277413). The company has also initiated a Phase 1 combination cohort evaluating IDE892 with IDE397, its proprietary MAT2A inhibitor, in non-small cell lung cancer and other solid tumors. IDEAYA plans to initiate another Phase 1 combination cohort with Roche's RG6505 in MTAP-deleted, RAS-mutant PDAC during the second half of 2026. The newly announced collaboration adds GDC-7035 as an additional KRAS-directed combination partner within the broader IDE892 development program. According to IDEAYA, the company is pursuing multiple combination strategies for IDE892, including combinations with IDE397, pan-RAS inhibitors, KRAS-mutant-specific therapies, and its lead CDKN2A compound. IDE892 shows potential best-in-class characteristics. IDEAYA reported that IDE892 has approximately 1,400-fold selective MTA-PRMT5 cooperative binding compared with SAM-PRMT5 cooperative binding. The company also reported that IDE892 was designed to lack brain penetration, with the aim of maximizing its therapeutic window. These properties are intended to support the development of IDE892 in combination with other targeted therapies, including MAT2A inhibitors, pan-RAS inhibitors, KRAS-directed therapies, and CDKN2A-directed approaches. IDEAYA also reported that IDE892 has a CYP3A4 IC50 greater than 45 micromolar and did not demonstrate time-dependent inhibition across the seven major cytochrome P450 enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The findings were based on full kinetic CYP inactivation assays. According to IDEAYA, these drug-interaction characteristics may further support the development of IDE892 as a combination partner for targeted therapies. Terms of the collaboration. Under the clinical collaboration, IDEAYA and Genentech will each retain all commercial rights to their respective compounds, including their use as monotherapies and in combination regimens. Genentech will sponsor the clinical combination study, while IDEAYA will provide IDE892. The companies will maintain joint governance over the clinical supply collaboration and conduct of the study. Clinical significance. The collaboration will evaluate IDE892 in combination with Genentech's KRAS G12D inhibitor GDC-7035 within Genentech's Phase I/II clinical program (NCT06619587), which is evaluating GDC-7035 as a single agent and in combination with other anticancer therapies in patients with KRAS G12D-mutant advanced solid tumors. The new collaboration will specifically assess the combination in patients with PDAC harboring both MTAP deletion and a KRAS G12D mutation. The agreement also expands IDEAYA's strategy of evaluating IDE892 across multiple rational combination approaches in molecularly selected cancers. Reference. About the Writer Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.

Business Insider

Aug 8th, 2026

LifeSci Capital sticks to its Buy rating for IDEAYA Biosciences (IDYA).

LifeSci Capital sticks to its Buy rating for IDEAYA Biosciences (IDYA). Aug. 8, 2026, 08:35 AM LifeSci Capital analyst Charles Zhu maintained a Buy rating on IDEAYA Biosciences today and set a price target of $58.00. * Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions * Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Kura Oncology, and IDEAYA Biosciences. According to TipRanks, Zhu has an average return of 25.9% and a 63.60% success rate on recommended stocks. IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $51.91. Based on IDEAYA Biosciences' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $8.86 million and a GAAP net loss of $112.45 million. In comparison, last year the company had a GAAP net loss of $77.49 million Read More on IDYA:

IDEAYA Biosciences

Medical Director, Drug Safety and Pharmacovigilance

About the job